Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Vice President, Business Development
Company: Innovent Biologics, Inc.
个人简介:
Blake Salisbury currently leads BD activities as the VP of Business Development at Innovent Biologics, a China based innovative biopharmaceutical company.  Blake has 27 years of experience in pharma/biotech, primarily in business development (20 years), but also in sales, marketing, and pricing. While at Innovent, Blake has in-licensed and out-licensed various early stage assets to/from partners in China, he led a global co-development deal to develop and commercialize a bispecific antibody with Hanmi Pharmaceuticals, and in 2018 he in-licensed 3 late stage oncology small molecules from Incyte for the China market. Prior to joining Innovent, Blake spent almost 24 years with Eli Lilly and Company where he closed over 50 transactions of various types, many of which were notable transactions with Chinese companies, starting as early as 2006.  Blake’s last position at Lilly was as a Senior Director of Corporate Business Development – responsible for in-license, out-license, and M&A activities supporting Lilly’s various Business Units.
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Founder, Chairman & CEO
Company: Ascletis Pharma Inc.
个人简介:
Dr. Jinzi J. Wu is Founder, Chairman and CEO of Ascletis which was founded in April 2013. Ascletis is an innovative R&D driven biotech with three commercial products. Led by Dr. Wu, Ascletis (1672.HK) became the first pre-revenue biotech listed on the Hong Kong Stock Exchange in 2018 and raised US$400M. Dr. Wu has more than 20-year experience covering R&D, GMP manufacturing and commercialization in Big Pharma and biotech. Prior to founding Ascletis, he was Vice President at GSK R&D in USA. He also held various R&D positions from Sr. Scientist to Vice President at Novartis, Immunex/Amgen and Ambrilia in USA and Canada. Dr Wu obtained his PhD in Cancer Biology from University of Arizona.
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: CFO
Company: I-MAB Biopharma
个人简介:
As the Chief Financial Officer, Jielun Zhu, MBA, CFA, is in charge of the overall financial strategy and management, capital investment, corporate finance and investor relations. He is a veteran and expert in the finance industry, with over 11 years of experience in investment banking. From December 2015 to July 2018, prior to joining I-Mab, he served as a managing director and Asia Head of Healthcare Investment Banking and Capital Markets in Hong Kong for Jefferies Group LLC, a global full-service investment bank with a strong focus in healthcare.At Jefferies, Mr. Zhu advised many biotechnology and healthcare clients globally on IPOs and other financings, as well as mergers and acquisitions. From August 2008 to September 2015, he worked for the Deutsche Bank Group in its Hong Kong office, occupying a succession of positions culminating in Director in the Corporate Finance Division, which entailed working with leading clients in the healthcare and other sectors in Greater China. From July 2007 to July 2008, he was an investment banker in Hong Kong with UBS AG. Before investment banking, Mr. Zhu was a strategy consultant in Boston focused on serving clients in the US pharmaceutical and biotechnology industry.Mr. Zhu earned his MBA from Harvard Business School with distinction in June 2007 and his Bachelor of Arts degree with honors in mathematics-economics from Wesleyan University. He is also a Chartered Financial Analyst (CFA) charter holder.
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Vice President, Strategy & Business Development
Company: Luye Pharma Group Ltd.
个人简介:
Ms. Sammy (Chinese name: Hua Jiang) is currently the Vice President of Luye Life Science Group, responsible for strategy, business development, and Investor relationship. Ms. Jiang has over 22 years of experience in pharmaceutical industry. Ms. Jiang had led over thirty of pharma and healthcare M&A, License In and License Out deals and cross boarder collaborations in the past 10 years. Ms. Jiang holds a Doctor of Business Administration from United Business Institute, a Master’s degree in Business Administration from KEDGE Business School (previously known as Euromed Management School), and a Bachelor’s degree of Economics from Economy School, Fudan University. She is also an economist certified by the Ministry of Human Resources and Social Security of the People’s Republic of China. She is also the Vice Chairman of KEDGE AEMBA Alumni Association. She is the freelance writer for Healthcare executive magazine, China Pharmaceutical technology economics and management magazine, etc, and been invited to attend and make the speech in some related seminar/conference. Ms. Jiang is also the Program Professor for Yeehong Business School, Shenyang Pharmaceutical University and Yantai University Pharmaceutical College.